Ultralow-Dose Adjunctive Methadone with Slow Titration, Considering Long Half-Life, for Outpatients with Cancer-Related Pain

Background: The unique properties of methadone make it attractive for use in cancer pain. The use of very low initial doses of adjunctive methadone is a promising strategy given its simplicity and potentially reduced risk profile. Objective: To understand if an ultralow-dose (ULD) methadone protocol...

Descripción completa

Detalles Bibliográficos
Autores principales: Chary, Srini, Abdul-Razzak, Amane, Galloway, Lyle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241322/
https://www.ncbi.nlm.nih.gov/pubmed/34223466
http://dx.doi.org/10.1089/pmr.2020.0034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241322/
https://www.ncbi.nlm.nih.gov/pubmed/34223466
http://dx.doi.org/10.1089/pmr.2020.0034

Ejemplares similares